Louiza Labs
Digital humans replace animal trials
San Francisco, CA, US
Louiza Labs develops physics-driven AI software that simulates human biology to generate synthetic medical datasets and create multi-organ digital twins. This technology accelerates medical device development and testing, and trains autonomous surgical robotics. The company also develops a pharmaceutical evidence synthesis platform.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →
How We Help
Problem Statement
Louiza Labs addresses the challenges of lengthy and manual pharmaceutical evidence synthesis for drug safety and efficacy, and the slow and costly processes of medical device development and FDA approval.
Core Technology
Physics-driven AI software that simulates human biology to generate synthetic medical datasets and create multi-organ digital twins; pharmaceutical evidence synthesis platform
Key Differentiators
Medical device development timelines reduced by 2-4 years; Medical device development and testing accelerated by 95+ times compared to traditional methods; Automates evidence synthesis timeline from months to days
Clinical Focus
Women's Health; Endocrinology; Surgery; Orthopedics; Cardiology; Emergency Medicine
Company Info
- Business Model
- B2B SaaS
- Founded
- 2025
- Total Funding
- 5,000,000
- Website
- www.louiza.ai/
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Physics-driven multi-organ AI models validated for in silico FDA trials. Accepted by regulatory agencies including FDA as computational evidence for medical device approval.
MedStartr Index Score
?What do you think of Louiza Labs?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.